The FDA has approved the sale of a generic version of the
angiotensin-receptor blocker medication losartan, and generic
versions of two other ARBs may soon follow.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.